Our Founders & Vision
Built by Managed Access experts
Designed for the future of Managed Access Programs
Maprium was founded on a simple observation: Managed Access has changed, but the technology supporting it has not.
What was once viewed as an operational process has evolved into a strategic capability that influences evidence generation, commercial readiness, market access, governance and patient access across the pharmaceutical industry.
Yet many organizations continue to manage global programs using spreadsheets, disconnected systems and manual/fragmented processes that were never designed to provide enterprise-wide visibility, governance or control.
We believe there has to be a better way.
Our mission is to help pharmaceutical companies transform Managed Access into a strategic enterprise capability.
We do this by providing the technology, governance and operational insight needed to plan, govern, execute and continuously improve Managed Access programs through one purpose-built platform.
Our goal is not simply to digitize existing processes.
It is to give organizations the visibility, control and confidence to scale Managed Access while retaining ownership of their operations, data and strategic direction.
Because better managed programs mean faster, safer and more equitable access for patients who can't wait.
Why We Created Maprium
Maprium was created by professionals who have spent decades designing, delivering and governing Managed Access programs for pharmaceutical companies around the world.
We've experienced first-hand the operational complexity that develops as programs expand across countries, products, vendors and regulatory environments.
We've seen organizations struggle with fragmented systems, inconsistent processes and limited oversight, making it difficult to deliver the governance and strategic insight that today's programs demand.
Creating a New Category
We believe Managed Access has outgrown the tools traditionally used to run it. As programs become increasingly strategic, organizations need more than manual processes, isolated databases or vendor-owned systems.
They need enterprise infrastructure.
That's why we're defining a new category: the Managed Access Operating System.
Maprium provides the foundation that enables pharmaceutical companies to coordinate programs across functions, partners and geographies while maintaining complete visibility, governance and control.
What We Believe
We believe
governance should be built into everyday operations rather than added retrospectively.
We believe
technology should simplify complexity, not create more of it.
And we believe the best software is built by people who truly understand the work it supports.
Unlike organizations whose expertise begins with software development, our expertise begins with Managed Access.
Technology is how we deliver our solution—not our starting point.
That distinction matters because every decision within the platform reflects decades of practical experience supporting pharmaceutical companies to deliver complex global programs safely, consistently and compliantly.
The result is a platform that mirrors the realities of Managed Access and helps organizations move from fragmented operations to strategic control.
Meet The Team
Behind Maprium is a team with extensive experience spanning Managed Access, Clinical Trials, pharmaceutical operations, supply chain, regulatory affairs, governance, healthcare technology and life sciences.
Together, we've helped shape some of the industry's most complex global Managed Access programs and are committed to helping pharmaceutical companies build the next generation of Managed Access capability.
John Ryan
CTO
John is a technology executive with more than 20 years’ experience building and scaling software platforms in clinical research, healthcare, and medical education.
As CTO of Longboat Clinical, he helped grow the company into a leading clinical trial technology provider prior to its acquisition by Advarra, where he later served as SVP of Sponsor Technology and Chief Scientist.
Our Investors & Advisors
Maprium is supported by a strong group of investors and advisors who share our vision to help pharmaceutical companies to enable patients to access the medicines they need in a timely, safe and compliant manner.
Natalie Douglas
Natalie is a multi-award-winning executive, board advisor, and investor with more than 25 years of experience leading private equity and venture-backed healthcare, pharma services, and MedTech organizations.
Widely recognized as a pioneer in global Managed Access Programs, she built and led IDIS (now Clinigen), transforming it into the leading international provider of Early and Expanded Access Programs and helping shape what is now considered the industry standard for global managed access.
Natalie has continued to work closely with innovative healthcare and technology businesses as a board member, investor, and strategic advisor.
Known for combining commercial insight with operational excellence, Natalie has built a reputation for scaling high-growth organizations, navigating complex global markets, and driving innovation in healthcare delivery.
Gerard Ryan
Gerard is a qualified Pharmacist and Chartered Director (IoD) with a distinguished track record as an entrepreneur, investor and business leader.
Over the course of his career, he has successfully founded, scaled and exited four companies through trade sales, primarily within the healthcare, MedTech and life sciences sectors.
In addition to his entrepreneurial achievements, Gerard is an active angel investor with investments in more than 38 companies, supporting innovative businesses across MedTech, healthcare and life sciences.
He is widely recognized for combining deep sector expertise with strategic leadership and a strong focus on commercializing novel products and unique business models.
Ken O'Connell
Ken is an experienced finance and business leader with a strong track record in the healthcare, pharmaceutical, medical device, and technology sectors.
He currently serves as Finance Director of RGH Capital, where he supports investments in start-ups across technology, medical, healthcare, and biotech industries. Previously, he was Chief Financial Officer of Firecrest Clinical, contributing to the company’s growth and its successful acquisition by ICON plc.
Ken was also co-founder and Chief Executive Officer of Longboat Clinical, where he led all aspects of the business from inception through to its successful acquisition by Advarra.
In addition to his executive leadership roles, he is an active investor and board member in a number of technology companies operating within the pharmaceutical and medical device sectors.
Mark Good
Mark is Head of Private Equity at Abbey International Finance, where he is responsible for sourcing, structuring and managing investments across Ireland and the UK.
His work spans strategy, corporate finance, portfolio management and business growth, with a focus on supporting management teams.
Mark works with investee companies and investment partners on funding, strategy and value creation initiatives. He also serves in board-level roles across a number of Abbey’s portfolio companies.
Mark holds an engineering degree and an MBA, which support a practical and analytical approach to his investment work.
Niall McKeon
Niall is a Chartered Accountant with over 30 years’ experience, including over two decades in C-suite and senior leadership roles.
He has extensive expertise across finance, private equity, investment strategy and business growth, with a strong track record of supporting and scaling businesses across multiple industries and international markets.
Niall also serves as a board member and non-executive director for a number of investee companies. Since 2009, he has been Chief Financial Officer of Abbey International Finance, where he plays a key role in driving the firm’s investment and growth strategy.
Take a personalized 15-minute tour
To request a demo, discuss your access challenges or learn more about Maprium, please use the secure form.